ArticleJournal of gastrointestinal oncology2026
Risk factors and prognostic implications of upper or middle mediastinal lymph nodes metastasis and recurrence in esophagogastric junction carcinoma.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk factors for upper and middle mediastinal lymph node (UMMLN) metastasis and the prognostic value of mediastinal lymphadenectomy (MLA) in patients with esophagogastric junction cancer (EGJC) remain unclear. This study aims to identify predictors for UMMLN metastasis or recurrence in EGJC with an esophageal invasion length (EIL) of >2 cm to ≤4 cm, and to clarify the histology specific prognostic impact of mediastinal dissection. Methods: We retrospectively reviewed patients who underwent radical resection for stage II-IV EGJC with an EIL of >2 cm to ≤4 cm between 2000 and 2022. Risk factors for UMMLN involvement, defined as pathological metastasis or locoregional recurrence within 3 years, were evaluated. Postoperative outcomes were compared according to UMMLN involvement and histological subtype. Results: Among 43 patients with adenocarcinoma (AC) and 45 with squamous cell carcinoma (SCC), the proportion undergoing UMMLN dissection was similar. UMMLN involvement was identified in 20 patients (17 pathological metastases and 3 locoregional recurrences). Esophagus-predominant tumors [odds ratio (OR) 9.24, 95% confidence interval (CI): 1.11-77.2; P=0.04] and clinical N2 or higher (OR 3.7, 95% CI: 1.07-12.8; P=0.04) were independently associated with UMMLN involvement. However, the wide CI reflects a high degree of uncertainty, likely due to the limited number of events. Among patients with SCC, total MLA resulted in comparable survival rates between those with and without pathological UMMLN metastases, while patients with AC and UMMLN metastases had poor long-term outcomes. Conclusions: Nodal status and histological type, together with tumor epicenter, may help guide the indications for, and prognostic benefit from, UMMLN dissection in EGJC with an EIL of >2 cm to ≤4 cm. Nonetheless, the risk factors for UMMLN involvement remain to be completely elucidated, and further investigation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.